AMG 167

Drug Profile

AMG 167

Alternative Names: AMG-167

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Antibodies; Osteoporosis therapies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Metabolic bone diseases

Most Recent Events

  • 03 Jan 2017 Phase I development for AMG 167 is ongoing in USA
  • 16 Sep 2016 Preclinical data in bone disorders presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR - 2016)
  • 23 Jun 2011 Amgen completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01101048)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top